Mawahib Ahmed Elawad Abu Elgasim, Yousra Abdelmoniem Suleiman, Lobaina Abozaid, Dlal Alser Hassan Mohmmed, Soha Saad Aldin Mohamad Suliman, Duaa Hamd Abdulatif Farh
{"title":"他莫昔芬在苏丹妇女中的妇科副作用,喀土穆,苏丹,2020","authors":"Mawahib Ahmed Elawad Abu Elgasim, Yousra Abdelmoniem Suleiman, Lobaina Abozaid, Dlal Alser Hassan Mohmmed, Soha Saad Aldin Mohamad Suliman, Duaa Hamd Abdulatif Farh","doi":"10.4236/abcr.2023.124012","DOIUrl":null,"url":null,"abstract":"Background: In Sudan, the common endocrine therapy tamoxifen is prescribed to HR-positive patients, which is associated with a variety of complications such as hot flashes, vaginal discharge, and vaginal dryness. Objective: This study aimed to determine the gynecological side effects of tamoxifen among Sudanese women who have been diagnosed with breast cancer in Khartoum, Sudan. Methods: A retrospective cross-sectional study was conducted at Alzara Hospital in Al Amal Toure Revere, Sudan. A convenience sample of individuals previously diagnosed with breast cancer attended refer clinic. From October 2020 to September 2021, all patients attending were checked for eligibility. Results: A total of 100 patients were enrolled in the study; 60% of patients reported increased vaginal secretions after taking the drug, 28% reported normal vaginal secretions with no change, and 11% reported decreased secretions after taking the medication, while 22% developed vaginal bleeding, and 22% of the ultrasound results revealed endometrial masses among the study patients. Also, 54 percent of female patients experienced hot flashes after taking the medication, and 12% of women missed some doses of treatment. Conclusion: Tamoxifen results in several gynecological side effects in women with breast cancer. A high percentage of women in the study developed hot flashes, vaginal bleeding, and discharge, in addition to having ultrasound results showing endometrial masses among them.","PeriodicalId":67095,"journal":{"name":"乳腺癌(英文)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Gynecological Side Effects of Tamoxifen among Sudanese Women, Khartoum, Sudan, 2020\",\"authors\":\"Mawahib Ahmed Elawad Abu Elgasim, Yousra Abdelmoniem Suleiman, Lobaina Abozaid, Dlal Alser Hassan Mohmmed, Soha Saad Aldin Mohamad Suliman, Duaa Hamd Abdulatif Farh\",\"doi\":\"10.4236/abcr.2023.124012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: In Sudan, the common endocrine therapy tamoxifen is prescribed to HR-positive patients, which is associated with a variety of complications such as hot flashes, vaginal discharge, and vaginal dryness. Objective: This study aimed to determine the gynecological side effects of tamoxifen among Sudanese women who have been diagnosed with breast cancer in Khartoum, Sudan. Methods: A retrospective cross-sectional study was conducted at Alzara Hospital in Al Amal Toure Revere, Sudan. A convenience sample of individuals previously diagnosed with breast cancer attended refer clinic. From October 2020 to September 2021, all patients attending were checked for eligibility. Results: A total of 100 patients were enrolled in the study; 60% of patients reported increased vaginal secretions after taking the drug, 28% reported normal vaginal secretions with no change, and 11% reported decreased secretions after taking the medication, while 22% developed vaginal bleeding, and 22% of the ultrasound results revealed endometrial masses among the study patients. Also, 54 percent of female patients experienced hot flashes after taking the medication, and 12% of women missed some doses of treatment. Conclusion: Tamoxifen results in several gynecological side effects in women with breast cancer. A high percentage of women in the study developed hot flashes, vaginal bleeding, and discharge, in addition to having ultrasound results showing endometrial masses among them.\",\"PeriodicalId\":67095,\"journal\":{\"name\":\"乳腺癌(英文)\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"乳腺癌(英文)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4236/abcr.2023.124012\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"乳腺癌(英文)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4236/abcr.2023.124012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:在苏丹,常见的内分泌治疗他莫昔芬是给hr阳性患者开的,这与各种并发症如潮热、阴道分泌物和阴道干燥有关。目的:本研究旨在确定他莫昔芬在苏丹喀土穆被诊断为乳腺癌的苏丹妇女中的妇科副作用。方法:在苏丹Al Amal Toure Revere的Alzara医院进行回顾性横断面研究。一个方便的样本是以前被诊断患有乳腺癌的人参加了转诊诊所。从2020年10月到2021年9月,对所有就诊的患者进行了资格检查。结果:共纳入100例患者;60%的患者服药后阴道分泌物增加,28%的患者阴道分泌物正常,无变化,11%的患者服药后分泌物减少,22%的患者出现阴道出血,22%的患者超声结果显示子宫内膜肿块。此外,54%的女性患者在服药后出现潮热,12%的女性错过了一些剂量的治疗。结论:他莫昔芬对乳腺癌患者有多种妇科副作用。研究中有很大比例的女性出现了潮热、阴道出血和分泌物,此外超声结果还显示子宫内膜肿块。
Gynecological Side Effects of Tamoxifen among Sudanese Women, Khartoum, Sudan, 2020
Background: In Sudan, the common endocrine therapy tamoxifen is prescribed to HR-positive patients, which is associated with a variety of complications such as hot flashes, vaginal discharge, and vaginal dryness. Objective: This study aimed to determine the gynecological side effects of tamoxifen among Sudanese women who have been diagnosed with breast cancer in Khartoum, Sudan. Methods: A retrospective cross-sectional study was conducted at Alzara Hospital in Al Amal Toure Revere, Sudan. A convenience sample of individuals previously diagnosed with breast cancer attended refer clinic. From October 2020 to September 2021, all patients attending were checked for eligibility. Results: A total of 100 patients were enrolled in the study; 60% of patients reported increased vaginal secretions after taking the drug, 28% reported normal vaginal secretions with no change, and 11% reported decreased secretions after taking the medication, while 22% developed vaginal bleeding, and 22% of the ultrasound results revealed endometrial masses among the study patients. Also, 54 percent of female patients experienced hot flashes after taking the medication, and 12% of women missed some doses of treatment. Conclusion: Tamoxifen results in several gynecological side effects in women with breast cancer. A high percentage of women in the study developed hot flashes, vaginal bleeding, and discharge, in addition to having ultrasound results showing endometrial masses among them.